Novozymes A/S provided earnings guidance for the year 2022. For the year, the company expects a strong first half and good momentum across the business leading to a narrowed organic sales growth outlook from 4-8% to now 6-8%. Sales reported in Danish kroner expected to be around 8 percentage points higher than the organic sales growth rate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
387.9 DKK | -0.15% | +0.78% | +4.53% |
Apr. 08 | Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023 | CI |
Mar. 26 | China to speed up 'new productive forces', vice president says | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.53% | 25.83B | |
-26.59% | 3.25B | |
+11.44% | 1.73B | |
-27.06% | 380M | |
-81.65% | 216M | |
-9.88% | 116M | |
-14.86% | 51.4M |
- Stock Market
- Equities
- NSIS B Stock
- News Novonesis A/S
- Novozymes A/S Provides Earnings Guidance for the Year 2022